One of the primary goals of Myeloma Patients Europe (MPE) is to provide education, information, and support to member organisations to facilitate their development, capacity and sustainability. To support this aim, MPE’s Scholarship and Capacity Building Programme invites member organisations to submit applications for an activity they want to implement to benefit the myeloma and AL amyloidosis patient community in their country. Following a comprehensive application and selection process, 10 successful applicants receive a grant of up to €3,000, in addition to any support required by members to help implement their idea (e.g. planning and logistical help, design advice etc). In this publication, we summarise and showcase the projects supported through the MPE Scholarship and Capacity Building Programme in 2021. All projects and events have been extremely successful, thanks to the hard work and efforts of all our members.

If you are interested in applying to the MPE Scholarship and Capacity Building programme, you can find more information by visiting the MPE website (www.mpeurope.org) or by emailing info@mpeurope.org.
The rate of research progress in myeloma has accelerated, and sometimes there is a gap between the accumulated scientific information and the availability of new products in the healthcare basket.

The patients experience recurrent remission of the disease at unpredictable times when each return is accompanied by a more advanced treatment line and new drugs that have not been given in a previous treatment line. Currently, there are five approved treatment lines in the Israeli healthcare basket and when a patient finishes with all existing treatment lines, their path to new treatment is blocked and they need individual treatment from different sources to extend their life.

Therefore, AMEN found it necessary to provide information to patients and family members regarding clinical trials suitable for their medical condition and to make clinical trials accessible to myeloma patients.

To achieve their goal, with the support of the MPE Scholarship, AMEN translated the questionnaire on the site (www.trialjectory.com) into Hebrew and adapted it for myeloma patients. This site analyses all relevant treatment options and presents only what is a match for the patient's condition in easy-to-understand language.

They also organised a workshop at the annual conference and Dr Yael Cohen gave a lecture in which she explained when and why to participate in clinical research and demonstrated the use of the site to locate personalised clinical research.

On December 23rd 2021, AMEN held a demonstration of the system for haematologists and they soon plan to launch the system, which will analyse the relevant treatment options on their website and provide a demonstration for their patients.

At the end of last year, AMEN held a webinar to show haematologists how the system worked.

To improve early diagnosis, the Armenian Hematology Association (AHA) organised a series of webinars with the aim to improve knowledge, skills and general awareness for non-specialists. They also developed brochures for general practitioners, patients and caregivers.

In Armenia, there are almost no reports on Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering myeloma. It is reasonable to suggest that often primary care physicians, as well as many general practitioners and non-specialists, are dismissing the clinical signs and symptoms suggestive of MGUS/Smoldering myeloma. Based on the estimation from the Armenian Hematology Association, on average each patient loses three to six months due to incorrect evaluation and diagnostic workup. Therefore, improving the knowledge, skills and general awareness among non-specialists is essential in tackling this issue.

The Armenian Hematology Association, with the support of MPE’s Scholarship, organised a series of webinars and seminars, whose aim was to educate non-specialists on the proper assessment, differential diagnostics and referral of patients susceptible to MGUS/Smoldering myeloma. Various educational materials were provided to general practitioners, patients and caregivers as well.

A professional team of health care providers and educators created specialised webinars and seminars for each target group explaining their role and their perspective about the disease.

The Armenian Hematology Association organised five seminars and two webinars for doctors and translated educational brochures for general practitioners, patients and caregivers.
The Association of Cancer Patients in Finland is committed to sharing quality information with myeloma patients. To do so, they translated into Finnish a webinar on personalised medicine for those patients who were not able to watch English webinars. It would also provide the latest updates and developments in this disease.

The Blodkreftforeningen website has information related to diagnoses, symptoms, treatment and research. The organisation believes it is important to update and improve the information on the diagnoses pages regularly. With the help of MPE’s Scholarship, they were able to coordinate haematologists to review and amend the existing information to ensure it was accurate and up to date.

The links to the updated diagnoses pages are:
- https://www.blodkreftforeningen.no/amyloidose
- https://www.blodkreftforeningen.no/myelomatose

Blodkreftforeningen also arranged a webinar for AL amyloidosis patients and their relatives after discovering that the AL amyloidosis patients in Norway did not receive sufficient information. The webinar was organised in May 2021 and the footage was published on their website: https://www.blodkreftforeningen.no/webinar.

The same information was also published on their Facebook and YouTube channel (https://youtu.be/mQuAmN3NAuk).

The organisation received positive feedback from their members saying the information on the website was useful. Members and health professionals also expressed that the webinar on AL amyloidosis was interesting and informative. They hope to have increased the understanding of AL amyloidosis in patients, relatives and healthcare professionals.

The live stream event on their Facebook page was viewed 400 times and over 60 people participated in the live stream event, which, given the rarity of the disease, was an impressive turnout.

ASSOCIATION OF CANCER PATIENTS IN FINLAND

+ Finland

https://www.syopapotilaat.fi

info@syopapotilaat.fi

The Association of Cancer Patients in Finland, the MPE member in Finland, considers sharing reliable, relevant information to cancer patients as one of their primary tasks, but due to limited resources in Finnish, they are not able to produce videos for Finnish patients very often.

With the aim of keeping Finnish myeloma patients up to date about latest updates in treatment and care in this disease, in 2021 with the support of MPE’s Scholarship and Capacity Building Programme, this organisation was able to translate the webinar on “Personalised medicine in the treatment of Multiple Myeloma and AL amyloidosis” into Finnish.

This webinar was originally organised by MPE in English and it was given by Dr. Francesca Bonello, haematologist in the Università degli Studi di Torino, in Italy.

The new, translated webinar was uploaded onto their YouTube channel and shared with their myeloma patient network.

The Association of Cancer Patients in Finland believed the webinar would offer some new information to those who were not able to watch English webinars, and help them gain a better understanding of myeloma and how it could be treated.

In order to keep its myeloma patients informed, Blodkreftforeningen reviewed and updated the content available on its website. It also organised a webinar on AL amyloidosis, which gathered 400 views. The live stream event had an audience of more than 60 people.
In 2021, the Carita Foundation, with the support of MPE’s Scholarship, conducted the MM Patient European Forum - Patient Academy, which consisted of educational meetings for patients led by healthcare experts, as well as forums to facilitate knowledge exchange between leaders of patient organisations. The highlight of the 2021 Patient Academy series was a panel in which experts discussed the most important challenges and the situation of multiple myeloma patients in Poland as compared to Europe.

The following live webinars were held during the Forum:

- New standards of therapies
- How to support patients during the COVID-19 pandemic
- Therapies for newly diagnosed patients
- Immune disorders
- Fracture treatment
- Rehabilitation of multiple myeloma patients

The forum was followed by an expert panel on treatment standards and new challenges in multiple myeloma during the COVID-19 pandemic. The panel was attended by over 150 people.

Cancer patients who eat well and maintain a healthy body weight often tolerate treatment side effects better. Good nutrition helps the body replace blood cells and tissues broken down by treatment; a healthy lifestyle plays a key role in keeping the body strong, supporting the immune system and reducing the risk of heart disease, and certain types of cancers. Despite this, there are very limited resources and research on nutrition and cancer. Patients find it difficult to get science-based advice, which can lead to them following misinformation and myth.

HEMA, with the support of the MPE Scholarship and Capacity Building Programme, created and distributed booklets entitled “Nutrition and Blood Cancers”. Developed by a specialist nutritionist, the booklet contained information on the following:

- Foods to be avoided by blood cancer patients
- Foods to be consumed by blood cancer patients
- Best foods to be consumed during and after chemotherapy
- Impact of nutrition on overall wellbeing

The booklet was distributed at the University Clinic for Haematology in Skopje to patients, carers and other interested community members. The publication was also made available online on HEMA’s website and social media channels. In addition, with the help of the scholarship provided by MPE, HEMA translated the booklet into Albanian. The translation was a great success, as the Albanian minorities living in North Macedonia can now access the booklet in their native language.

Overall, the booklet had a significant impact on myeloma and AL amyloidosis patients, providing an excellent guide for the community and answering common questions that blood cancer patients have about nutrition.
Members' activities · MPE

**Cancer patients with haematological disorders or haematopoietic stem cell transplants are at high risk of COVID-19 infections due to multiple comorbidities and immunosuppression. Thus, there was an emerging need to create awareness in cancer patients to protect themselves from COVID-19.**

In early 2021, it was generally acknowledged that cancer patients, patients with haematological malignancies and transplant patients were at increased risk, but there was no scientific questionnaire or survey to assess personalised risk.

KANKOBIRKAN (BiRKANKO), along with the support of MPE’s scholarship, launched a survey to assess the risk of getting COVID-19. The survey was published online, and it went live on covid19riskim.org. More than 400 patients and 200 caregivers took part in the survey.

KANKOBIRKAN (BiRKANKO) also worked with students at the University of Montreal Polytechnic, Canada, to design an app that would gather data to calculate the risk of each participant. The answers provided by each participant were reviewed by a specialist team assigned by KANKOBIRKAN (BiRKANKO) and each respondent received their calculated risk assessment report in three days.

The team also prepared a report for the governor’s office and the health authorities.

The results enabled the organisation to understand the risks to myeloma patients in Turkey contracting COVID-19 and helped individuals take necessary measures to reduce their risk.

Since the organisation was founded, 463 families have been supported through APCL Cares.

In 2021, MPE supported the Portuguese Association Against Leukaemia and Other Blood Cancers (APCL) to provide financial support for haematological and oncological patients. The programme, APCL Cares, directly assists patients facing economic hardships caused or aggravated by their haematological disease. Over the past year, due to the COVID-19 pandemic, APCL received an increased number of requests from patients for social support grants.

When patients receive a diagnosis, there are social, emotional and economic implications for the patient and their family. Patients and caregivers must travel frequently, and sometimes for long distances, which can create an undue financial burden for families. In addition, as treatment can often be a long process, economically fragile families can face rising debts or struggle to obtain essential goods. APCL Cares seeks to ease the financial stress families face so that patients and carers can focus exclusively on treatment and recovery.

APCL partners with social workers in hospital haematology units across the country. A patient’s request for a social support grant is administered by the social worker and approved through a comprehensive review process by the APCL Board. Since the organisation was founded, 463 families have been supported through APCL Cares with a total of €170,000 in grants awarded. In 2021 alone, with the support of MPE’s Scholarship, APCL provided 115 grants, helping 36 patients and families with financial difficulties.
Blood cancer patients in Slovenia have very good access to novel therapies and diagnostics, but they don't have suitable access to rehabilitation during and after treatment. A rehabilitation programme is an essential aspect of comprehensive care, helping patients get back to their social life and work.

The L&L Association, supported by MPE's Scholarship, organised a rehabilitation programme for patients with blood cancers, 'Together on the Path to Health'. This consisted of three key modules - physical, nutritional and psychosocial - featuring monthly workshops led by a psychologist, monthly dietary group consultations with a nutritionist, weekly exercise with a physical therapist or kinesiologist and various forms of consulting services.

The patients who were interested in participating in "Together on the Path to Health" had to complete an interview with a haematologist, who assessed their medical condition before enrolling them in the programme. Each patient participated in the programme for six months. During this time, the patients attended all activities, and the participating experts and programme coordinator were available for any questions. The programme also had an "info phone", where patients could call any day of the week at any time and receive support from an employee of the L&L Association.

The patients were informed of the programme and the possibilities of enrolment through printed posters and leaflets placed in hospitals. They were also informed about the programme via the patient community on social media. The workshops were recorded and made available on the L&L Association's YouTube channel, website (www.nazajvzivljenje.si) and Facebook page.

The rehabilitation programme made an important contribution to the quality of life of patients with myeloma and AL amyloidosis, and it resulted in better treatment outcomes. Patients recovered faster and more easily during and after treatment and it was easier for them to return to social and work environments.

Due to the COVID-19 pandemic, the programme was run online and thus accessible to many patients from all regions of Slovenia.

Myeloma and AL amyloidosis patients in Romania often struggle to find accurate information about their diagnosis. To fill this knowledge gap, SOS Mielom, with the support of MPE’s Scholarship, developed seven different brochures containing information about myeloma and AL amyloidosis, which were distributed in 14 hospitals across the country. The brochures were entitled:

- Little things that make a difference for myeloma and AL amyloidosis patients
- Suggestions and written advice by people with myeloma for people with myeloma
- Myeloma and pain: guide on symptoms and complications
- Exercise for patients with myeloma
- Guidelines for caregivers of patients with myeloma
- Guidelines for patients with refractory or relapsed myeloma
- Guidelines for the wellness of patients with myeloma

SOS Mielom also translated MPE's myeloma guide from English to Romanian so that patients could obtain more information about their diagnosis.

The organisation reported that the brochures and myeloma guide were informative and helpful for the patient community.